<DOC>
	<DOC>NCT00796510</DOC>
	<brief_summary>As sitaxsentan is the agent most highly selective for ETA (Endothelin Type A (receptor)), and does not significantly impact sildenafil pharmacokinetics the combination of most promise for pulmonary arterial hypertension (PAH) therapy is these two oral drugs administered in combination.</brief_summary>
	<brief_title>Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<mesh_term>Sitaxsentan</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Previously enrolled in B1321001 for at least 4 weeks. Previously enrolled in B1321003, discontinued from the study. Completed the B1321003 study as planned. Treated with an investigational drug (other than sitaxsentan or sildenafil in either B1321001 or B1321003) or device that has not received regulatory approval within the 30 days prior to Baseline/Day 1 or during the study.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>endothelin receptor antagonist (ETRA)</keyword>
	<keyword>sitaxsentan</keyword>
</DOC>